
**ALZET Comments:** Antibody, anti CD41; PBS; SC; Mice; 3 days; Dose (1 μg/day); animal info (male BALB/c mice (> 8 weeks of age)); 4470 and 4464 are anti-CD41 antibodies; immunology; Therapeutic indication (immune thrombocytopenia);


**ALZET Comments:** apelin-F13A, DC101, Antibody, anti-VEGFR2; CSF, artificial; CSF/CNS (tumor); Mice; 1002; 2004; 14 and 28 days; Dose (30 or 60 μg of apelin-F13A, 0.8 mg of DC101); apelin-F13A is a mutant APLNR ligand, DC101 is a VEGFR2-blocking antibody; ALZET brain infusion kit 3 used; cancer (glioblastoma);


**ALZET Comments:** Antibody, NMO-IgG; Complement, human; CSF/CNS (intrathecal); CSF/CNS (lateral ventricle);; Rat; 1003D; 3 days; Dose (10 μg NMO-IgG and 50 μL (5μg/μL) human complement); NMO aka Neuromyelitis optica;


**ALZET Comments:** Anti-HSP90a/b monoclonal antibody, mouse IgG; CSF, artificial; CSF/CNS (right lateral ventricle); Mice; 1004; 14 days; Dose (164 ng/mL-HSP90, IgG); aCSF: 148.3mM NaCl, 3mM KCl, 1.4mM CaCl2, 0.8mM MgCl2, 0.75mMNa2HPO4, and 0.195mMNaH2PO4 used; animal info (8 w animal info (8 weeks old, 28-33 g, female, ddY); ALZET brain infusion kit 3 used; Brain coordinates (anteroposterior: −0.22mm, mediolateral: +1mm, dorsoventricular: −2.5mm); bilateral cannula used; cyanoacrylate adhesive; spinal cord injury;


**ALZET Comments:** Antibody, anti Nerve growth factor; SC; Mice; 1002; 2 weeks; Dose (10 μg/Kg/hour); Controls received mp w/ vehicle; animal info (9-10-week-old female C57BL/6 N mice weighing 18-22 g); spinal cord injury;


**ALZET Comments:** CTRP3 antibody; Immunoglobulin G; SC; Mice; 4 weeks; Dose (2.5 μg/g/day); animal info (Male C57/B6 mice weighing 10-12g); cardiovascular;


**ALZET Comments:** Antibody, anti-NRR1; PBS; CNS/CSF (lateral ventricle); Mice; 1004; 10-50 days; Dose (1 μg/μL); Controls received mp w/ vehicle; anti-NRR1 is a NOTCH1 blocking antibody; ALZET brain infusion kit used; Brain coordinates (coronal suture, 2mm right lateral to midline, 4mm into the lateral ventricle); cancer (medulloblastoma);

ALZET Comments: Antibody, anti-Nogo-A; CSF/CNS (Intrathecal), SC; Monkey (Macaca fascicularis); 2ML2; 4 weeks; Dose (3 mg/ml); One pump administered the treatment intrathecally to the cervical spinal cord, whereas the other pump delivered the antibody close to the lesioned site in M1 below the dura; Multiple pumps per animal (2);


ALZET Comments: Antibody, anti–Macrophage migration inhibitory factor; Antibody, anti–Macrophage migration inhibitory factor; CSF/CNS (third ventricle); Mice; 2002; Dose (2 μg/day); animal info (8-week old female C57BL/6 mice); Brain coordinates (1.8 mm caudal to bregma, 5.0 mm ventral to the sagittal sinus); Therapeutic indication (antipsychotic therapy);


ALZET Comments: Antibody, anti-GCSF neutralizing antibody, Immunoglobulin G, pre-immune; Saline; CSF/CNS (nucleus accumbens); Mice; 1007D; 7 days; Dose (1 ug/day); animal info (Male, C57BL/6 J, 7 weeks old, 20–25 g ); Multiple pumps per animal (2); Brain coordinates (From bregma: anteroposterior, +1.5; mediolateral, + 1.0; dorsoventral, −4.5); bilateral cannula used; The cannulae were permanently fixed to the skull with Loctite adhesive; dependence;


ALZET Comments: Antibody, rabbit anti-CX3CR1; PBS; SC; Rat; 2006; 6 weeks; Dose (0.15 μl/h); Controls received mp w/ vehicle; animal info (Adult male, 200–250 g, Sprague–Dawley rats); neurodegenerative (Epilepsy);


ALZET Comments: Antibody A11; compound 59; Saline; IP, SC; Mice; 1004, 2004; 4 weeks, 8 weeks; Controls received mp w/ vehicle; animal info (male, C57BL6J, 25–30g); pumps replaced every 4 weeks; Dose (Antibody: 1.5 ug/day; Compound 59: 5, 25, or 50 μg/kg/day);


ALZET Comments: Antibody, anti-Nogo-A; CSF/CNS (intrathecal); Rat; 2ML2; 2 weeks; animal info (adult female Long-Evans rats); post op. care (animals received analgesics and antibiotics);


ALZET Comments: shRNA, NM_133534.1; antibody, CX3CR1; NaCl; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; animal info (male, Sprague Dawley, P7); ALZET brain infusion kit 3 used; ALZET brain infusion kit 3 used; Brain coordinates;


ALZET Comments: Antibody, anti-nogo-A 11C7; CSF/CNS (Ipsilesional lateral ventricle); Rat; 2ML2; 14 days; Controls received mp with IgG1; animal info (Long evans) ischemia (stroke); Therapeutic indication (stroke).


ALZET Comments: Antibody, anti-CX3CR1; CSF/CNS (right lateral ventricle); Mice; 1007D; 7 days; Controls received mp w/ rabbit IgG isotype; animal info (p25 C57Bl/6 mice); ALZET brain infusion kit 3 used; Brain coordinates (AP, 20.70; ML, 21.25; DV, 22.15).


ALZET Comments: Antibody (hCRACM1-IgG); YM-58483; Saline; Intralipose; SC; Mice; 1004; 28 days; hCRACM1-IgG Dose (1 or 10 mg/kg), YM058483 Dose (1.5mg/kg); 0.3% of ethanol in 1M PBS; Controls received mp w/ vehicle or rabbit IgG; animal info (adult male Wistar rats); post op. care (0.03 mg/kg buprenorphine administered SC); ALZET brain infusion kit used; Brain coordinates (anterior/posterior, -3.8; lateral/medial, +2.5; dorsal/ventral, +3.0).


ALZET Comments: Antibody, anti-TGF ; Angiotensin II; CSF/CNS (left ventricle); Mice; 1002; 1004; 2 weeks; Dose (TGF neutralizing antibody: 50 μg/d; Ang II: 500 ng/kg/min); animal info (8-10 week old male adult wild-type, Tg, 34Lan, and B6 129P-Cx3cr1tm1Litt/l mice); Multiple pumps per animal (second pump with angiotensin II implanted 3 or 7 days after first pump); antihypertensive; ALZET brain infusion kit 3 used; Brain coordinates (0.5 mm caudal to Bregma; 1 mm lateral to the midline; 2 mm ventral to the dura); cardiovascular.


ALZET Comments: Bumetanide; Antibody, anti-pan-neurotrophin receptor p75; Ethanol; PBS; CSF/CNS; Rat; 2002; 3 days; Dose (bumetanide: 86ng/24 hours, p75NTR antibody: 6.67 ug/mL); 0.3% of ethanol in 1M PBS; Controls received mp w/ vehicle or rabbit IgG; animal info (adult male Wistar rats); post op. care (0.03 mg/kg buprenorphine administered SC); ALZET brain infusion kit used; Brain coordinates (anterior/posterior, -3.8; lateral/medial, +2.5; dorsal/ventral, +3.0).


ALZET Comments: Antibody, anti-mouse-GM-CSF, Antibody, rat isotype (IgG2a); PBS; CSF/CNS; Rat; 2002; 3 days; Controls received mp w/ vehicle; pumps replaced every 4 weeks; long-term study.


ALZET Comments: unclustered ephrin A5 Fc, clustered (C) ephrin A5 Fc, antibody, IgG; CSF, artificial; CSF/CNS; Mice; 1007D; Controls received mp w/ vehicle; animal info (C57BL/6, 5-6 weeks old) ALZET brain infusion kit 3 used; no stress “All mice...
survived, and no apparent behavioral discomfort was observed. " (see pg. 41 ); Therapeutic indication (angiogenesis, Temporal lobe epilepsy); Dose (50 ug/mL).


**ALZET Comments:** Angiotensin II; antibody, Angiotensin II type 1-Receptor Autoantibody; Saline; Rat; 2002; Controls received mp w/ vehicle; animal info (250 g) Infusion began on GD 12-19 ; Therapeutic indication (Hypertension, inflammation, pregnancy); Dose (50 ng/kg/min).


**ALZET Comments:** Sonic hedgehog protein, Cyclopamine, antibody, anti-VEGF; PBS; CSF/CNS; Rat; 1007D; 7 days; Dose (1 mg/mL Shh, 20 μM Shh plus Cyc, 25 μg/ml Shh plus VEGF antibody); animal info (Male Sprague–Dawley rats); Cyclopamine is a sonic hedgehog protein inhibitor; Brain coordinates (bregma -0.8 mm anteroposterior, ±1.5 mm mediolateral, and -4.5 mm dorsoventral).


**ALZET Comments:** Immunoglobulin G1, anti-Nogo-A antibody 11C7; Immunoglobulin G1, anti-cyclosporin A; CSF/CNS; Rat; 2ML2; 2 weeks; animal info (female Sprague-Dawley rats weighing 200-250 g); Therapeutic indication (spinal cord injury).


**ALZET Comments:** Antibody, salusin-beta; Saline; SC; Rat; 2004; 4 weeks; Controls received mp w/ control IgG; animal info (male, Sprague Dawley, 220-250g); cardiovascular; immunology; used wound clips; Dose (1 ug/kg/hr); see video with implantation procedure.

**Q5497:** J. Xu, C. V. Bishop, M. S. Lawson, B. S. Park and F. Xu. Anti-Mullerian hormone promotes pre-antral follicle growth, but inhibits antral follicle maturation and dominant follicle selection in primates. Hum Reprod 2016;31(7):1522-30

**ALZET Comments:** Antibody, anti-Mullerian hormone; PBS; Intraovarian; Monkey (macaque); 2ML2; 4 weeks; animal info (female, hemi-ovariectomized, adult); pumps replaced; Dose (500 ng/h);.


**ALZET Comments:** Antibody, anti-tau; MC-1; Tau 5; TOMA; CSF/CNS (lateral ventricle); Mice; 28 days; Controls received mp w/IgG1; animal info (10–12 month-old); neurodegenerative (Alzheimer's); behavioral testing (open field; water maze); immunotherapy; MC-1, Tau 5 and TOMA are an anti-tau antibodies; This route of administration allowed for behavioral testing as well as pathology evaluation; Dose (1 mg/ml);.


**ALZET Comments:** Oligomer, amyloid-beta, Antibody, anti-amyloid-beta oligomer; CSF, artificial; CSF/CNS (hippocampus); Rat; Controls received mp w/ vehicle and IgG1 antibody; Guide cannula used for injection and infusion; neurodegenerative (Alzheimer's); Schematic of guide cannula and osmotic pump (p. 4).


**ALZET Comments:** Antibody, 31C6; antibody, POM1; PBS; CSF/CNS; Mice; 2004; 21 days; animal info (BL6.129-Prnp); post op. care (SC injections of buprenorphinum, funixin, and 5% glucose; Sulfadoxinum and sugar were added into water for 1 week post op); MRI; pumps primed in 37C PBS for 24 hours; used PEEK tubing;.
**ALZET Comments:** Placenta growth factor, recombinant human; antibody, interleukin-1B; PBS; SC; Mice; 1007D; 7 days; Controls received mp w/ vehicle or control antibody; animal info (male, C57BL6, 8 weeks old, STZ); immunology; diabetes; Dose (PIGF 10 ug/mouse; anti-IL-1B 1 ug/day).

**ALZET Comments:** Antibody, Interleukin-10 receptor; CSF/CNS; Mice; 2006; 42 days; Controls received mp w/ saline; animal info (SOD1 G93A, 60 days old); neurodegenerative (amyotrophic lateral sclerosis); behavioral testing (hindlimb reflex); pumps primed overnight in 37C saline; used dental cement; Dose (3.6 ug/day).

**ALZET Comments:** Antibody, anti-KLK8; Saline; CSF/CNS (lateral ventricle); Mice; 2004; 4 weeks; Dose: (62 mg/kg/d); Controls received mp w/ vehicle and mp w/ rat IgG; animal info (transgenic and wild type mice); ALZET brain infusion kit 3 used; Brain coordinates (20.2 Bregma, 10.9 parasagittal); neurodegenerative (Alzheimer’s);.

**ALZET Comments:** Antibody, CX3CR1; saline; CSF/CNS (ventricle); Rat; 1 week, 6 weeks; Controls were Electrode- and cannulae-implanted nonstimulated rats; animal info (Adult male Sprague Dawley rats, 200-250 g); functionality of mp verified by EEG; functionality of mp verified by EEG; brain tissue distribution; Cannula placement verified via expression of antibody; Dose (1 mm posterior and 1.5 mm lateral to the bregma and 3.5 mm ventral to the flat skull position (with the bregma as reference)); Interesting “Our results are the first evidence that epileptic seizures induce an immune response in the retina. It has a potential to become a novel non-invasive tool for detecting brain inflammation through the eyes” pg. 1;.

**ALZET Comments:** Angiotensin II, Angiotensin II Type 1 Receptor Autoantibodies; IP; Rat (pregnant); 2001; animal info (13 days pregnant); Therapeutic indication (Preeclampsia, pregnancy, hypertension); Dose (50 ng/kg; AT1-AA 1:40 dilution);.

**ALZET Comments:** Antibody, beta-2-glycoprotein, hydroxychloroquine; Water, distilled; mice (pregnant); 1002; animal info (Age 2-3 months old; pump inserted day 8 of pregnancy); Dose (200 ug/mouse/day).

**ALZET Comments:** Antibody, CK3CR1; saline; CSF/CNS (ventricle); Rat; 1 week, 6 weeks; Controls were Electrode- and cannulae-implanted nonstimulated rats; animal info (Adult male Sprague Dawley rats, 200-250 g); functionally of mp verified by EEG; functionally of mp verified by EEG; brain tissue distribution; Cannula placement verified via expression of antibody; Dose (1 mm posterior and 1.5 mm lateral to the bregma and 3.5 mm ventral to the flat skull position (with the bregma as reference)); Interesting “Our results are the first evidence that epileptic seizures induce an immune response in the retina. It has a potential to become a novel non-invasive tool for detecting brain inflammation through the eyes” pg. 1;.
ALZET Comments: Antibody, Ly6G; immunoglobulin G2a, rat; SC; Mice; 2004; 8 weeks; Animal info (male, DEN-injured nfkβ1-/- or WT, 22 weeks old); cancer (hepatocellular carcinoma).

ALZET Comments: Antibody, anti-SEMA 4D, monoclonal; CSF/CNS (intrathecal, subarachnoid space); Rat; 2002; 14 days; Control animals received mp w/ control IgG; animal info (Sprague Dawley, male, 8 wks old).

ALZET Comments: Antibody, anti-MK; Mice; 1007D; 1 day; Controls received mp w/ control antibody; animal info (male, Mdk +/-, 10-14 weeks old, 25-35g); cardiovascular; bp measured using radiotelemetry; Dose (5.0 ug/hr).

ALZET Comments: Antibody, monoclonal, BBS; CSF/CNS (right lateral ventricle); mice; 2006; 42 days; Controls received mp w/ isotype-matched non relevant MAb; animal info (male Hemizygous B6SJLTgN (SOD1G93A) 1 Gur mice); brain infusion cannula used; neurodegenerative (ALS); immunology; antibodies infused; MAb aka Monoclonal antibody; Ketamine and Xylazine anesthesia; Dose (1.5 mg/mL); Brain coordinates; l-2mm [Bregma] in the anterio-posterior direction, 2.8mm in mediolateral direction and 3mm depth.

ALZET Comments: Antibody, AC133xCD3 bispecific; PBS; CSF/CNS; Mice (nude); 1007D; 7 days; Controls received mp w/ control antibody; animal info (NMR I nude, 6-8 weeks old); ALZET brain infusion kit 3 used; cancer (glioblastoma multiforme); immunology; cyanoacrylate adhesive.

ALZET Comments: CXCL1; antibody, CXCL1; CXCR2 antileukine hexapeptide; morphine; CSF/CNS (intrathecal); Rat; 5 days; 2 days; Controls received mp w/ saline; animal info (male, Sprague Dawley, 250-275g, adult); behavioral testing (tail flick response); dependence; used PE10 intrathecal catheter tubing.

ALZET Comments: Antibody, CTA 157-2; Rat; 7 days; Controls received mp w/ vehicle; animal info (male, Sprague Dawley, 200g); cardiovascular.


ALZET Comments: Antibody, interleukin-4Ra; CSF/CNS (hippocampus); Mice; 1004; 28 days; Controls received mp w/ control antibody; animal info (APPswe/SP1dE9, 7-5 months old); ALZET brain infusion kit 3 used; neurodegenerative (Alzheimer's disease); immunology; pumps primed 48 hours in 37C saline;


ALZET Comments: Antibody, anti-Nogo-A; CSF/CNS (intrathecal); Rat; 2ML2; 2 weeks; Animal info (male, Sprague-Dawley, adult, 200-250g); ALZET brain infusion kit 1 used;


ALZET Comments: Antibody, neuromyelitis optica; PBS; CSF/CNS; Mice; 1003D; 3 days; Controls received mp w/ control IgG; animal info (BALB/c an CD59-/-, 8-10 weeks old); neurodegenerative (neuromyelitis optica); behavioral testing (motor function);


ALZET Comments: Antibody, anti-Nogo-A; CSF/CNS (intrathecal); Rat; 2ML1; 7 days; Controls received sham surgery; animal info (male, Sprague Dawley, 5-6 weeks old, 190-220g); functionality of mp verified by immunohistochemistry and Western blotting; brain tissue distribution; learning; behavioral testing (motor skill task); Cannula placement verified via Nissl staining; used dental cement and bone screws; pumps and cannula removed after 4 weeks;

ALZET®
Bibliography

ALZET Comments: Interleukin-2, murine; antibody, anti-interleukin-2; PBS; SC; Mice (transgenic); 10 days; Controls received mp w/ vehicle; animal info (HLA-DR3); comparison of injection vs mp; immunology.

ALZET Comments: Antibody, anti-aminoprocalcitonin; Saline; IP; Rat; 2001D; 18 hours; Controls received mp w/ control antibody; animal info (male, Wistar, 280-300g); tissue perfusion (peritoneum); immunology; peptides; Catheter used to cannulate peritoneum.

ALZET Comments: Antibody, mAb9.2.27; PEG; CSF/CNS; Rat (nude); 2001D; Controls received mp w/ vehicle; animal info (rnu/rnu, 8-10 weeks old); 24% PEG used; cancer (glioblastoma).

ALZET Comments: Antibody, CX3CR1; CSF, artificial; CSF/CNS; Mice; 14 days; Controls received mp w/ vehicle; animal info (WT, adult); vehicle pumps replaced after 7 days with pumps filled with test agent; behavioral testing (Morris Water Maze; contextual and auditory-cued fear conditioning; olfactory memory); used guide cannula; used three stainless-steel screws and dental cement.

Q3604: E. Porlan, B. Marti-Prado, J. M. Morante-Redolat, A. Consiglio, A. C. Delgado, R. Kypta, C. Lopez-Otin, M. Kirstein, I. Farinas and I. Farinas. MT5-MMP regulates adult neural stem cell functional quiescence through the cleavage of N-cadherin. NATURE CELL BIOLOGY 2014;16(629-+
ALZET Comments: Antibody, N-cadherin extracellular domain; Ara-C; CSF/CNS; Mice; 6 days; 7 days; Controls received mp w/ control antibody; animal info (Mmp24 knockout); good methods (picture of pump infusion pg.635); AraC pumps removed after 6 days.

ALZET Comments: DU51; antibody, anti-MHC-1; antibody, anti-CD8; DMSO; PBS; IP; Rat; 14 days; 28 days;; Controls received mp w/ control peptide; animal info (male, LEW.1W and LEW.1A); pumps replaced every 7 days with pumps filled with test agent; functionality of mp verified by decreased activity of targets; "... to improve the efficacy of the treatment and because such small peptides are rapidly eliminated from the recipient's body, we tested mini-osmotic pumps with a constant i.p. delivery of 20.8 ng/hour of peptide for 28 days, starting on day 7 before transplantation." pg 2507;

ALZET Comments: Antibody, brain-derived neurotrophic factor; CSF/CNS (intrathecal); Rat; 2001; 3 days; Controls received mp w/ control IgG; animal info (male, Wistar, 250-300gt); post op. care (buprenorphine 0.05-0.1 mg/kg SC); peripheral nerve injury;

ALZET Comments: Antibody, anti-interleukin-1a; antibody, anti-interleukin-6; antibody, tumor necrosis factor-alpha; antibody, macrophage inflammatory protein-1 alpha; CSF/CNS (intrathecal); Rat; 1002; 2 weeks; Controls received mp w/ control antibody; animal info (female, Sprague Dawley, adult); functionality of mp verified by decreased activity of targets; used silicone tubing 0.3 mm ID for catheter; catheter was fixed to surrounding muscle with 8-0 sutures; pumps removed after 2 weeks.

**ALZET Comments:** Antibody, Rat monoclonal antagonistic anti-IFNγ; Antibody, irrelevant rat IgG1 monoclonal; PBS; CSF/CNS (lateral ventricle); mice; 2004; 4 weeks; animal info (Hb9::GFP mice, 13-week); ALZET brain infusion kit 3 used; neurodegenerative (Amyotrophic lateral sclerosis); Glue and dental cement used to secure cannula to skull; Dose (300 ug/mL); Brain coordinates (0.3mm anterior and 1mm lateral relative to bregma; 2.6mm below the surface of the skull).


**ALZET Comments:** Antibody, TGF beta 1; Saline; SC; Rat; 2ML1; Control animals received mp w/ vehicle; animal info (Sprague Dawley, 200-260 g).


**ALZET Comments:** Antibody, anti-VEGFR-2; CSF/CNS; Mice; 1007D; 1 week; Controls received mp w/ control antibody; animal info (C57BL6, 8 weeks old); cancer (brain tumor).


**ALZET Comments:** Antibody, mouse monoclonal anti-Nogo-A 11C7; uridine, anti-bromodeoxy; CSF/CNS (intrathecal); Rat; 2ML2; 2 weeks; Controls received mp w/ control antibody; animal info (female, Long Evans, 3-7 months, 230-400g); ischemia (photothrombic); post op. care (Rimadyl 2.5mg/kg, Baytril 5mg/kg for 3 days; mannitol 20% injection 17 mg/kg; heating pad for 24h); behavioral testing (pellet grasping); pump and catheter removed after 2 weeks; used 32 gauge intrathecal catheter.


**ALZET Comments:** Antibody, neuropilin-1; PBS, Dulbecco’s; CSF/CNS; Rat; 1007D; 7 days; Controls received mp w/ vehicle; animal info (female, Sprague Dawley, 190-200g); Neuropilin-1 aka Nrp1; used Plastics One cannula; pumps primed overnight in 37C saline.


**ALZET Comments:** Antibody, rAb-53; complement, human; CSF/CNS (optic chiasm); Mice; 1003D; 3 days; Controls received mp w/ non-NMO control IgG and complement; animal info (AQP4+/+ and AQP4−/−, 8-10 weeks old); tissue perfusion (optic chiasm); immunology; Cannula placement verified via Evan’s blue dye; rAb-53 aka NMO-IgG.

ALZET Comments: Antibody, anti-Nogo-A 11C7; CSF/CNS (intrathecal); Mice; 2ML2; 2 weeks; Controls received mp w/ control antibody (anti cyclosporin A); animal info (male, Lister hooded, adult, 150-200g); good methods (pg 2947, schematic of positioning of pumps p2948); spinal cord injury; neurodegenerative (spinal cord injury); behavioral testing (staircase task, ladder walking, gait analysis, grip strength, heat sensation, von Frey hair test); used 32 gauge catheter from ReCathco.


ALZET Comments: Antibodies, anti-tau; PBS; CSF/CNS (lateral ventricle); mice; 2006; 3 months; long-term study; controls received mp w/ vehicle anti-AB HJ3.4 and PBS; P301S, tau pathology, 5 months old; long-term study; pumps replaced every 6 weeks; neurodegenerative (tau pathology).


ALZET Comments: Antibody, anti-Nogo-A 11C7; CSF/CNS; CSF/CNS (intrathecal); Monkey (macaque); 2ML2; 4 weeks; Controls received no pump treatment; animal info (macaca fascicularis, 1 female, 7 male, 4-6 years old, 3.5-6.5 kg); Multiple pumps per animal (2); behavioral testing (modified Brinkman board task, rotative Brainkman board task, Brinkman box task); One pump delivered IT, other delivered CSF/CNS using catheter; no cannula used, see pg.741; pumps removed after 4 weeks; used antibody concentration of 3 mg/ml.


ALZET Comments: Antibody, anti-1.25D3-MARRS; CSF, artificial; SC; Mice; 1007D; 6 days; Animal info (6 weeks old, ddY, male); cyanoacrylate adhesive; Brain infusion kit (3) used; behavioral testing (object recognition memory test, open field test); 1,25D3-MARRS has many synonyms including Pdia3, ERp57, and GRP58.


ALZET Comments: Antibody, notch1-activating; Jagged 1-Fc-anti-Fc complex; CSF/CNS; Mice; 1003D; 3 days; Controls received mp w/ aCSF; animal info (male, Fisher); behavioral testing (ladder rung walking test, limb placing test, elevated body swing test, cylinder test); Neuroscience paper; ischemia.


ALZET Comments: Antibody, fibroblast growth factor-2;; CSF/CNS; Mice; 1002; 8 weeks; Animal Info. (Hypoxic-ischemic mice, 6 weeks old, CD-1); Pumps replaced (every 2 weeks); Ischemia (hypoxic ischemic brain injury); Behavior testing (Rotarod performance, forelimb-use asymmetry test, grip strength test).


ALZET Comments: Antibody, rat anti-mouse IgG macrophage colony-stimulating factor; SC; Mice; 1002; 2 weeks; Controls received mp w/ control antibody IgG2a; animal info (C57BL6, 8 weeks old); cardiovascular; immunology.
ALZET Comments: Antibody, mAb9.2.27; PEG; CSF/CNS; Rat (nude); 2001D; 1 day; Controls received mp w/ IgG2a control isotype; animal info (Hsd:RH-Foxn1 rnu, 8-10 weeks old); 24% PEG used; cancer (U251-NG2 tumors, glioblastoma); immunology;.

ALZET Comments: Antibody, 69, mouse monoclonal; antibody, 147, mouse monoclonal; CSF/CNS (intrathecal); Rat; 2ML2; 2 weeks; Control animals received mp w/ control antibody; animal info (Sprague Dawley, female, wks old, 210 g); spinal cord injury; post op care (baytril, buprenorphine).

ALZET Comments: Antibody, anti-Nogo-A 11C7; PBS; CSF/CNS (intrathecal); Rat; 2ML2; 2ML4; 2 weeks; 4 weeks; Controls received mp w/ control antibody or PBS; animal info (male, Long Evans, 2-3 months old, 300g); post op. care (Rimadyl 5 mg/kg injection SC, Baytril 5 mg/kg injection SC for 72 hours at 12 hour intervals); behavioral testing (locomotor activity, anxiety, open field test, elevated plus maze); toxicology; “This procedure ensured antibody delivery into the CSF at a constant flow rate for 2 or 4 weeks.” pg 53;.

ALZET Comments: Antibody, leukemia inhibitory factor neutralizing; PBS; CSF/CNS (lateral ventricle); Mice; 1007D; 7 days; Dose (2 micrograms per day); Controls received mp w/ vehicle; animal info (female, C57BL6, 7-9 weeks old); ALZET brain infusion kit 3 used; Brain coordinates ((from bregma, 0.3mm anterior, 0.8 lateral);.

ALZET Comments: Antibody, anti CX3CRI; Fractalkine; Antibody, anti interleukin-beta; Saline; CSF/CNS (cisterna magna); Rat; 2001; 4 days; Controls received mp w/ vehicle; animal info (male, Sprague Dawley, 210-260g); post op. care (benzyl penicillin potassium, 2000U); behavioral testing (Rota-rod performance, Water tap reaching performance); immunology; peptides.

ALZET Comments: Antibody, anti interleukin-10; CSF/CNS; Mice; 1007D; 7 days; Controls received mp w/ control IgG; animal info (female, C57BL6, 7-9 weeks old); ALZET brain infusion kit 3 used; spinal cord injury; behavioral testing (open field, grid walk, inclined plane);

ALZET Comments: mAb TF9-10H10; monoclonal antibody anti tissue factor;; PBS; SC; Mice (nude); 1002; 2 weeks; Controls received mp w/ IgG diluted to equal concentration; animal info (20-25g); ALZET brain infusion kit 3 used; cancer (Glioma); “Since it has been shown that osmotic pumps are able to deliver molecules up to 2 cm from the injection site in the brain,
this system appeared to be most suitable for our purposes.” pg 517; Therapeutic indication (Glioma, p53); Dose (500 ug/mL);

ALZET Comments: Antibody, interleukin-6; SC; Rat; 1004; 28 days; Controls received mp w/ IgG; immunology; animal info (male, 220-240g); functionality of mp verified by IL-6 protein levels (western blot, high-sensitivity ELISA).

ALZET Comments: Antibody; anticlusterin-a/b; Immunoglobulin G, anti-rabbit; ICV; Mice; 6 days; Controls received mp w/anti-rabbit IgG; animal info (8-12 weeks); Dose (2 ug per day);

ALZET Comments: anti-SOD1 monoclonal antibodies (mAbs); CSF/CNS (lateral ventricle); mice; not specified; not specified; FALS transgenic mice; anti SOD1 monoclonal antibody; neurodegenerative (Amyotrophic Lateral Sclerosis); paper does not mention ALZET much, or pump model.

ALZET Comments: antibody, monoclonal anti-SOD1; CSF/CNS (ventricles); mice; animal info: FALS transgenic mice; anti SOD1 monoclonal antibody; neurodegenerative (Amyotrophic Lateral Sclerosis); paper does not mention ALZET much, or pump model;

ALZET Comments: Antibody, anti-beta 1 integrin; CSF/CNS (striatum); Mice; 28 days; Control animals received mp w/ isotype control; animal info (C57BL/6, female).

ALZET Comments: Antibody, interleukin-1 beta; CSF/CNS; Rat; 1003D; Animal info (Sprague Dawley, male, 260-270 g); ischemia.

ALZET Comments: Antibody, OS2966; SC; Mice; 1004; 28 days; Control animals received mp w/ immunoglobulin G; animal info (female, athymic, 5-8 wks old); OS2966 is a beta 1 antibody; cancer (glioblastoma); dose-response (Fig. 6); mp were used to block B1 integrin, and found that this can inhibit the ability of tumor cells to bind a broad spectrum of ECM ligands like fibronectin, collagen IV, and laminin.

**ALZET Comments:** Antibody, monoclonal, human; CSF/CNS; Mice; 2006; 50 days; Animal info (>20g, 65-115 days old); functionality of mp verified by measuring residual volume; measurement of tissue and serum HuMabs levels; pumps replaced every 50 days; good methods; long-term study.


**ALZET Comments:** Antibody, human IgG; Saline; CSF/CNS (intrathecal); Rat; 2001; 3 days; 7 days; Controls received mp w/ vehicle; animal info (Female, Wistar, 200-230g); spinal cord injury; post op. care (Baytril for one week, manual bladder emptying twice per day); behavioral testing (locomotor behavior); tissue perfusion (spinal cord); pump attached to mechanical microconnector system (mMS).